NCT04609891View on ClinicalTrials.gov

Avatrombopag on the Treatment of Thrombocytopenia Induced by Chemotherapy of Malignant Tumors

NACompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

May 26, 2020

Primary Completion Date

May 16, 2021

Study Completion Date

May 16, 2021

Conditions
Thrombocytopenia
Interventions
DRUG

Avatrombopag

10×109/L\<PLT\<75×109/L, avatrombopag tablet 60 mg once a day for 5-10 days.

Trial Locations (1)

230000

Anhui Provincial Cancer Hospital, Hefei

All Listed Sponsors
lead

Anhui Provincial Cancer Hospital

OTHER

NCT04609891 - Avatrombopag on the Treatment of Thrombocytopenia Induced by Chemotherapy of Malignant Tumors | Biotech Hunter | Biotech Hunter